Mogrify ^Company

Mogrify develops a systematic big data-science approach powered by next-generation sequencing and gene-regulatory data to identify the optimal combination of transcription factors (in vitro) or small molecules (in vivo), needed to convert any mature cell type into any other mature cell type without going through a pluripotent stem cell or even a progenitor cell-state. The Company applies this approach to address the issues of efficacy, safety, and scalability currently associated with cell therapy development and manufacturing, which is estimated to represent a $30 billion USD market opportunity and is rapidly growing. Mogrify was founded on 2016 and is headquartered in Cambridge, United Kingdom.